
Cancer-Associated Nerve Injury Leads to Chronic Inflammation and Immunotherapy Resistance
Key Takeaways
- Cancer cells degrade nerve protective covers, causing nerve injury, chronic inflammation, and immune exhaustion, leading to immunotherapy resistance.
- Targeting signaling pathways involved in cancer-induced nerve injury can reverse inflammation and improve treatment responses.
A study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation.
Cancer cells can break down the protective covers around nerves, causing nerve injury that triggers chronic inflammation leading to immune exhaustion and eventual resistance to
The study, published today in
“These findings uncover novel mechanisms by which the immune system and nerves within the tumor microenvironment interact, revealing actionable targets that could transform the way we approach resistance to immunotherapy in patients with cancer,” said co-corresponding author
Tumors can sometimes infiltrate the space around nerves and nervous system fibers that are in close proximity, a process known as perineural invasion, which leads to poor prognosis and treatment escalation in various cancer types. However, little is known about how this invasion affects or interacts with the immune system.
The study, co-led by Amit,
Collaborating with the immunotherapy platform, part of the
Unfortunately, this inflammatory response gets caught in a chronic feedback loop as tumors continue to grow, repeatedly damaging nerves which then recruit and exhaust the immune system, ushering in an immunosuppressive tumor microenvironment that leads to treatment resistance. The study showed that targeting the cancer-induced nerve injury pathway at different points can reverse this resistance and improve treatment response.
Importantly, the authors point out that this reduced neuronal health is directly associated with perineural invasion and cancer-induced nerve injury, rather than a general cancer-induced effect, highlighting the importance of studying cancer-nerve interactions that can potentially contribute to cancer progression.
As part of MD Anderson’s
The multi-institutional study was a global collaboration between MD Anderson, Brigham and Women’s Hospital, the University of Michigan, Moffitt Cancer Center and Queens University. The study was supported in part by the James P. Allison Institute and the Cancer Neuroscience Program at MD Anderson. A full list of collaborating authors and their disclosures can be found with the



































